Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer
This study is a single-arm, open-label, exploratory clinical study, the main purpose is to evaluate the combination of envafolimab, lenvatinib VP-16 in the treatment of platinum-resistant recurrent epithelial ovarian cancer，primary fallopian tube cancer and primary peritoneal carcinoma.
Ovarian Cancer, Epithelial
DRUG: Envafolimab|DRUG: Lenvatinib|DRUG: VP-16
ORR, objective response rate, 6 months
OS, overall survival, 12 months|PFS, progression free survival, 12 months|DCR, disease control rate, 9 months|AEs AEs, ａ advers adverse events, 12 months
Platinum-resistant patients who have received at least 1 line chemotherapy in the past and the recurrence time is less than 6 months will receive envafolimab combined with lenvatinib and VP-16 for 6 cycles, followed by single-agent envafolimab maintenance therapy until disease progression, intolerable toxicity, or withdrawal of informed consent